298 80

Full metadata record

DC FieldValueLanguage
dc.contributor.author이창범-
dc.date.accessioned2017-03-22T05:47:51Z-
dc.date.available2017-03-22T05:47:51Z-
dc.date.issued2015-07-
dc.identifier.citationEndocrinology and Metabolism, v. 30, NO 3, Page. 272-279en_US
dc.identifier.issn2093-596X-
dc.identifier.issn2093-5978-
dc.identifier.urihttps://synapse.koreamed.org/DOIx.php?id=10.3803/EnM.2015.30.3.272-
dc.identifier.urihttp://hdl.handle.net/20.500.11754/26255-
dc.description.abstractBackground The present study evaluated the efficacy of a combination of ibandronate and cholecalciferol on the restoration of the levels of 25-hydroxyvitamin D (25[OH]D) and various bone markers in postmenopausal women with osteoporosis. Methods This was a randomized, double-blind, active-controlled, prospective 16-week clinical trial conducted in 20 different hospitals. A total of 201 postmenopausal women with osteoporosis were assigned randomly to one of two groups: the IBN group, which received a once-monthly pill containing 150 mg ibandronate (n=99), or the IBN+ group, which received a once-monthly pill containing 150 mg ibandronate and 24,000 IU cholecalciferol (n=102). Serum levels of 25(OH)D, parathyroid hormone (PTH), and various bone markers were assessed at baseline and at the end of a 16-week treatment period. Results After 16 weeks of treatment, the mean serum levels of 25(OH)D significantly increased from 21.0 to 25.3 ng/mL in the IBN+ group but significantly decreased from 20.6 to 17.4 ng/mL in the IBN group. Additionally, both groups exhibited significant increases in mean serum levels of PTH but significant decreases in serum levels of bone-specific alkaline phosphatase and C-telopeptide of type 1 collagen (CTX) at 16 weeks; no significant differences were observed between the groups. However, in subjects with a vitamin D deficiency, IBN+ treatment resulted in a significant decrease in serum CTX levels compared with IBN treatment. Conclusion The present findings demonstrate that a once-monthly pill containing ibandronate and cholecalciferol may be useful for the amelioration of vitamin D deficiency in patients with postmenopausal osteoporosis. Moreover, this treatment combination effectively decreased serum levels of resorption markers, especially in subjects with a vitamin D deficiency, over the 16-week treatment period.en_US
dc.description.sponsorshipThis study was supported by Dreampharma Corp., of Seoul, Korea.en_US
dc.language.isoenen_US
dc.publisherKorean Endocrine Societyen_US
dc.subjectIbandronateen_US
dc.subjectCholecalciferolen_US
dc.subject25-hydroxyvitamin Den_US
dc.subjectBone markersen_US
dc.titleEfficacy of a once-monthly pill containing ibandronate and cholecalciferol on the levels of 25-hydroxyvitamin D and bone markers in postmenopausal women with osteoporosisen_US
dc.typeArticleen_US
dc.relation.no3-
dc.relation.volume30-
dc.identifier.doi10.3803/EnM.2015.30.3.272-
dc.relation.page272-279-
dc.relation.journalEndocrinology and Metabolism Clinics of North America-
dc.contributor.googleauthorCho, In-Jin-
dc.contributor.googleauthorChung, Ho-Yeon-
dc.contributor.googleauthorKim, Sung-Woon-
dc.contributor.googleauthorLee, Jae-Won-
dc.contributor.googleauthorLee, Tae-Won-
dc.contributor.googleauthorKim, Hye-Soon-
dc.contributor.googleauthorKim, Sin-Gon-
dc.contributor.googleauthorChoi, Han Seok-
dc.contributor.googleauthorChoi, Sung-Hee-
dc.contributor.googleauthorLee, Chang Beom-
dc.relation.code2015023273-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidlekang-


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE